Jubilant Pharmova Ltd.

JUBLPHARMAHealthcare filings

We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.

Earnings calls

6 transcript(s)/analyst meet(s) served; 3 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 6 documents here); elsewhere sentences render unattributed.

Kind	Date	Period	Served
COVER_LETTER	20220528	2022-03-31	no
TRANSCRIPT	20220602	2022-03-31	yes
COVER_LETTER	20220802	2022-06-30	no
TRANSCRIPT	20220808	2022-06-30	yes
COVER_LETTER	20230203	2022-12-31	no
TRANSCRIPT	20230209	2022-12-31	yes
TRANSCRIPT	20260527	2026-03-31	yes

JUBLPHARMA

files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.

Identity


Statement division	general
Scope served	consolidated
Panels on this page	4

Market

No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.


Last close	1,063.85
52-week range	807.65 – 1181.2
Return 1M	18.65%
Return 3M	10.31%
Return 1Y	-1.52%
Return 3Y	151.59%
Return 5Y	72.26%
Market capitalisation	not shown — we could not confirm it
Shares outstanding	not shown — we could not confirm it
P/E	not shown — we could not confirm it
P/B	not shown — we could not confirm it
EV/EBITDA	not shown — we could not confirm it

Latest quarter filed — period ending 2026-06-30

In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.


Revenue from operations	2,229.00
Other income	20.00
Total income	2,249.00
Cost of materials consumed	638.00
Purchases of stock-in-trade	87.00
Changes in inventories	24.00
Employee benefit expense	754.00
Finance costs	54.00

Ownership — 2026-06-30, and the change from 2026-03-31

Holder	Per cent	Change
promoter and promoter group	0.48	0.00
institutions foreign	0.16	-0.00
institutions domestic	0.12	0.01
mutual funds	0.09	0.01
public	0.52	0.00

Documents on file

Class	Most recent	On file
COVER_LETTER	2022-12-31	3
TRANSCRIPT	2026-03-31	4

Financial statements

Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.

Quarterly results, as filed

Line	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31	2024-03-31	2024-06-30	2024-09-30	2024-12-31	2025-03-31	2025-06-30	2025-09-30	2025-12-31	2026-03-31	2026-06-30
Revenue from operations	1,600.00	1,553.00	1,678.00	1,587.00	1,680.00	1,677.00	176.00	1,732.00	1,752.00	1,822.00	1,929.00	1,901.00	1,966.00	2,122.00	2,290.00	2,229.00
Other income	13.00	9.00	4.00	9.00	10.00	36.00	1.00	14.00	22.00	9.00	12.00	12.00	10.00	20.00	24.00	20.00
Total income	1,613.00	1,562.00	1,682.00	1,596.00	1,690.00	1,713.00	177.00	1,746.00	1,774.00	1,831.00	1,941.00	1,913.00	1,976.00	2,143.00	2,314.00	2,249.00
Cost of materials consumed	440.00	410.00	442.00	428.00	464.00	432.00	50.00	465.00	469.00	467.00	584.00	520.00	565.00	592.00	643.00	638.00
Purchases of stock-in-trade	62.00	81.00	50.00	57.00	58.00	72.00	5.00	62.00	69.00	81.00	85.00	73.00	74.00	82.00	84.00	87.00
Changes in inventories	-19.00	-14.00	37.00	35.00	34.00	33.00	-2.00	35.00	16.00	26.00	-43.00	25.00	-42.00	42.00	-14.00	24.00
Employee benefit expense	535.00	568.00	534.00	548.00	532.00	582.00	56.00	553.00	564.00	560.00	591.00	591.00	636.00	706.00	767.00	754.00
Finance costs	42.00	51.00	56.00	62.00	66.00	71.00	7.00	71.00	61.00	56.00	53.00	49.00	50.00	56.00	56.00	54.00
Depreciation and amortisation	94.00	94.00	271.00	90.00	97.00	95.00	10.00	91.00	91.00	91.00	95.00	98.00	105.00	121.00	117.00	127.00
Other expenses	363.00	361.00	395.00	350.00	349.00	342.00	40.00	366.00	344.00	400.00	367.00	402.00	392.00	410.00	470.00	479.00
Total expenses	1,517.00	1,552.00	1,786.00	1,569.00	1,601.00	1,625.00	166.00	1,642.00	1,615.00	1,681.00	1,731.00	1,758.00	1,780.00	2,010.00	2,124.00	2,163.00
Profit before exceptional items and tax	96.00	10.00	-103.00	27.00	89.00	88.00	11.00	104.00	159.00	150.00	209.00	154.00	196.00	133.00	190.00	86.00
Exceptional items	-57.00	0.00	0.00	0.00	0.00	0.00	-17.00	396.00	-14.00	-19.00	-3.00	0.00	-6.00	-40.00	-14.00	0.00
Profit before tax	39.00	10.00	-103.00	27.00	89.00	88.00	-6.00	500.00	144.00	131.00	206.00	154.00	190.00	94.00	176.00	86.00
Current tax	93.00	-4.00	53.00	14.00	35.00	45.00	11.00	26.00	40.00	32.00	115.00	38.00	36.00	22.00	66.00	30.00
Deferred tax	-61.00	28.00	-39.00	5.00	1.00	-10.00	-10.00	-8.00	2.00	-2.00	-60.00	14.00	34.00	16.00	-9.00	0.00
Tax expense	31.00	25.00	14.00	19.00	36.00	35.00	1.00	18.00	42.00	30.00	55.00	52.00	70.00	38.00	57.00	30.00
Profit for the period	5.00	-16.00	-101.00	6.00	62.00	66.00	-6.00	482.00	102.00	101.00	151.00	102.00	120.00	56.00	119.00	56.00
Profit attributable to owners	5.00	-16.00	-98.00	6.00	62.00	67.00	-6.00	482.00	103.00	101.00	154.00	103.00	120.00	56.00	119.00	56.00
Profit attributable to non-controlling interests	-1.00	-0.00	-3.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-2.00	-0.00	-0.00	-0.00	-0.00	-0.00
Other comprehensive income	67.00	72.00	-34.00	10.00	34.00	17.00	-1.00	-4.00	30.00	64.00	-5.00	41.00	160.00	62.00	282.00	-19.00
Total comprehensive income	72.00	56.00	-135.00	16.00	96.00	83.00	-7.00	478.00	132.00	164.00	147.00	144.00	280.00	118.00	401.00	37.00
Earnings per share, basic	0.34	-0.98	-6.15	0.40	3.94	4.22	-3.69	30.44	6.47	6.37	9.71	6.49	7.59	3.52	7.55	3.57
Earnings per share, diluted	0.34	-0.98	-6.15	0.40	3.94	4.20	-3.68	30.35	6.46	6.36	9.68	6.47	7.57	3.52	7.52	3.56

Annual results, as filed

Line	2018-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31	2024-03-31	2025-03-31	2026-03-31
Revenue from operations	7,465.00	9,154.00	6,099.00	6,059.00	6,282.00	670.00	7,234.00	8,280.00
Other income	133.00	47.00	18.00	82.00	38.00	7.00	57.00	66.00
Total income	7,598.00	9,202.00	6,116.00	6,141.00	6,320.00	677.00	7,291.00	8,346.00
Cost of materials consumed	2,678.00	3,119.00	1,349.00	1,349.00	1,666.00	182.00	1,985.00	2,320.00
Purchases of stock-in-trade	243.00	277.00	168.00	202.00	252.00	24.00	297.00	313.00
Changes in inventories	-52.00	-255.00	20.00	-62.00	-41.00	8.00	35.00	11.00
Employee benefit expense	1,556.00	2,128.00	1,923.00	2,043.00	2,166.00	222.00	2,268.00	2,701.00
Finance costs	284.00	287.00	184.00	145.00	188.00	27.00	240.00	212.00
Depreciation and amortisation	415.00	462.00	349.00	382.00	554.00	38.00	369.00	440.00
Other expenses	1,615.00	1,939.00	1,243.00	1,442.00	1,462.00	145.00	1,476.00	1,675.00
Total expenses	6,739.00	7,957.00	5,235.00	5,501.00	6,248.00	646.00	6,670.00	7,672.00
Profit before exceptional items and tax	859.00	1,245.00	881.00	640.00	72.00	32.00	622.00	674.00
Exceptional items	0.00	-35.00	-21.00	0.00	-57.00	-17.00	360.00	-59.00
Profit before tax	859.00	1,211.00	860.00	640.00	16.00	15.00	981.00	614.00
Current tax	299.00	323.00	270.00	173.00	181.00	20.00	213.00	161.00
Deferred tax	-74.00	-11.00	27.00	45.00	-88.00	-10.00	-69.00	56.00
Tax expense	225.00	312.00	297.00	217.00	93.00	10.00	144.00	217.00
Profit for the period	634.00	898.00	836.00	413.00	-65.00	7.00	836.00	398.00
Profit attributable to owners	0.00	898.00	836.00	414.00	-61.00	8.00	839.00	398.00
Profit attributable to non-controlling interests	0.00	—	-0.00	-1.00	-4.00	-0.00	-3.00	-1.00
Other comprehensive income	65.00	33.00	174.00	244.00	220.00	5.00	85.00	546.00
Total comprehensive income	700.00	931.00	1,010.00	657.00	156.00	13.00	921.00	943.00
Earnings per share, basic	41.25	56.39	52.48	26.00	-3.83	4.87	52.99	25.15
Earnings per share, diluted	41.25	56.39	52.48	26.00	-3.83	4.86	52.85	25.08

Balance sheet, as filed

Line	2022-09-30	2023-03-31	2023-09-30	2024-03-31	2024-09-30	2025-03-31	2025-09-30	2026-03-31
Total assets	10,705.00	11,157.00	11,400.00	1,155.00	11,924.00	12,756.00	13,521.00	15,523.00
Non-current assets	7,084.00	7,394.00	7,793.00	767.00	8,423.00	9,179.00	10,062.00	11,413.00
Current assets	3,620.00	3,762.00	3,606.00	363.00	3,502.00	3,510.00	3,397.00	4,109.00
Property, plant and equipment	2,240.00	2,298.00	2,250.00	216.00	2,128.00	2,132.00	3,242.00	3,510.00
Capital work-in-progress	487.00	773.00	1,095.00	125.00	1,857.00	2,715.00	2,344.00	2,962.00
Goodwill	2,393.00	2,429.00	2,452.00	246.00	2,480.00	2,541.00	2,649.00	2,826.00
Other intangible assets	139.00	457.00	150.00	19.00	180.00	181.00	212.00	198.00
Inventories	1,410.00	1,381.00	1,328.00	129.00	1,162.00	1,129.00	1,228.00	1,232.00
Trade receivables	944.00	961.00	904.00	92.00	795.00	892.00	961.00	1,070.00
Cash and cash equivalents	846.00	1,014.00	974.00	96.00	1,077.00	1,088.00	623.00	1,267.00
Total equity and liabilities	10,705.00	11,157.00	11,400.00	1,155.00	11,924.00	12,756.00	13,521.00	15,523.00
Equity	5,471.00	5,392.00	5,401.00	542.00	5,927.00	6,239.00	6,572.00	7,096.00
Equity share capital	16.00	16.00	16.00	2.00	16.00	16.00	16.00	16.00
Other equity	5,460.00	5,383.00	5,394.00	542.00	5,925.00	6,239.00	6,576.00	7,077.00
Total liabilities	5,234.00	5,765.00	5,998.00	613.00	5,997.00	6,518.00	6,950.00	8,427.00
Non-current liabilities	3,743.00	3,992.00	4,208.00	424.00	4,051.00	4,353.00	4,861.00	5,888.00
Current liabilities	1,491.00	1,772.00	1,790.00	189.00	1,947.00	2,165.00	2,088.00	2,539.00
Borrowings, non-current	2,996.00	3,110.00	3,170.00	317.00	2,542.00	2,150.00	2,319.00	2,972.00
Borrowings, current	223.00	300.00	250.00	25.00	283.00	287.00	280.00	248.00
Trade payables	640.00	821.00	924.00	86.00	826.00	1,005.00	1,001.00	1,234.00

Cash flow, as filed

Line	2022-09-30	2023-03-31	2023-09-30	2024-03-31	2024-09-30	2025-03-31	2025-09-30	2026-03-31
Net cash from operating activities	208.00	661.00	531.00	97.00	328.00	1,072.00	369.00	1,227.00
Net cash from investing activities	-282.00	-544.00	-341.00	-61.00	636.00	488.00	-631.00	-1,260.00
Net cash from financing activities	-104.00	-157.00	-239.00	-43.00	-848.00	-1,453.00	-184.00	95.00
Purchase of property, plant and equipment	342.00	814.00	498.00	90.00	642.00	1,116.00	740.00	1,449.00
Net increase in cash	-138.00	30.00	-40.00	-6.00	120.00	132.00	-466.00	179.00
con:CFO.BEFORE_TAX	338.00	865.00	626.00	118.00	453.00	1,310.00	516.00	1,436.00
con:INTEREST_RECEIVED.OPERATING	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:INTEREST_PAID.OPERATING	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:DIVIDENDS_RECEIVED.OPERATING	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:TAX_PAID.OPERATING	129.00	204.00	94.00	21.00	125.00	238.00	148.00	209.00
con:CF_OTHER.OPERATING	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:INVESTMENTS_PURCHASED	0.00	13.00	0.00	1.00	0.00	1.00	0.00	0.00
con:INVESTMENTS_SOLD	0.00	1.00	0.00	1.00	952.00	952.00	0.00	0.00
con:PPE_DISPOSALS	7.00	19.00	5.00	1.00	2.00	5.00	32.00	102.00
con:CF_INVESTING.SUBSIDIARIES_SOLD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:CF_INVESTING.SUBSIDIARIES_ACQUIRED	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:CF_INVESTING.JV_SOLD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:CF_INVESTING.JV_ACQUIRED	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Who owns it

The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.

Holder	2023-03-31	2023-06-30	2023-09-30	2023-12-31	2024-03-31	2024-06-30	2024-09-30	2024-12-31	2025-03-31	2025-06-30	2025-09-30	2025-12-31	2026-03-31	2026-06-30
Promoter and promoter group	50.68	50.68	50.68	50.68	50.68	50.68	50.68	50.68	50.68	47.68	0.48	0.48	0.48	0.48
Domestic institutions	1.63	1.63	1.65	2.89	3.78	4.07	5.66	6.98	7.05	9.53	0.11	0.11	0.12	0.12
Mutual funds	—	—	—	—	—	—	—	—	—	6.01	0.07	0.08	0.08	0.09
Insurance companies	0.00	0.00	0.00	0.00	0.00	0.00	0.64	1.41	1.36	1.15	0.01	0.01	0.01	0.01
Foreign institutions	23.22	23.20	23.21	20.29	19.06	19.49	17.94	16.96	17.22	17.40	0.17	0.16	0.16	0.16
Public	49.19	48.74	48.74	48.74	48.74	48.74	48.77	48.77	48.77	51.77	0.52	0.52	0.52	0.52
Non-institutional	23.10	23.90	23.88	25.56	25.90	25.18	25.17	24.83	24.50	24.84	0.25	0.25	0.24	0.23
Shares outstanding	159281139	159281139	159281139	159281139	159281139	159281139	159281139	159281139	159281139	159281139	159281139	159281139	159281139	159281139

Related parties

Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.

Counterparty	Relationship	Type	Amount in the period	Transactions
Jubilant Pharma Limited	Immediate parent	Any other transaction, Interest received	9,533,630,000.00	11
Jubilant Pharma Holdings Inc.	Immediate parent	Any other transaction, Interest received, Purchase o	7,593,370,000.00	26
Jubilant Cadista Pharmaceuticals Inc.	Fellow subsidiary	Any other transaction, Interest received, Investment	3,060,010,000.00	30
Jubilant DraxImage Inc.	Fellow subsidiary	Any other transaction, Sale of goods or services	1,541,260,000.00	39
Jubilant HollisterStier LLC	Fellow subsidiary	Any other transaction, Dividend received, Purchase o	925,730,000.00	18
Jubilant Biosys Limited	Fellow subsidiary	Any other transaction, Dividend received, Inter-corp	698,030,000.00	18
Jubilant Pharma UK Limited	Fellow subsidiary	Any other transaction, Sale of goods or services	559,520,000.00	6
Drug Discovery and Development Solutions Limited	Fellow subsidiary	Any other transaction, Interest received	440,880,000.00	13
Jubilant Therapeutics Inc.	Fellow subsidiary	Any other transaction, Interest received, Investment	403,030,000.00	20
Jubilant Ingrevia Limited	Enterprise in which Key management	Any other transaction, Purchase of goods or services	328,330,000.00	39
Jubilant Generics Limited	Fellow subsidiary	Any other transaction, Sale of goods or services	238,740,000.00	9
Mr. Shyam S. Bhartia	Key management personnel	Any other transaction, Remuneration	112,020,000.00	2
PSI Supply NV	Step down subsidiary	Any other transaction, Sale of goods or services	94,330,000.00	4
Jubilant FoodWorks Limited	Enterprise in which Key management	Any other transaction, Sale of goods or services	83,270,000.00	8
Jubilant Pharma ME FZ-LLC	Fellow subsidiary	Any other transaction, Interest received, Sale of go	81,200,000.00	7

What management said

Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.

Date	Quarter
2023-02-09	Q3FY23	Read the call
2022-08-08	Q1FY23	Read the call
2022-06-02	Q4FY22	Read the call

Some earlier announcements under this heading are covering letters only — no transcript was attached.

What they said about it, quarter by quarter

Topic	Q1FY23	Q3FY23	Q4FY22
Capex	We are running a very large and robust CapEx plan.	—	—
Capital allocation	—	No, my only reason for asking this is, since the time of acquisition, we would have incurred almost Rs.	—
Costs	—	You're saying what is the source of the cost savings?	—
Debt and cash	Let's say, do you have a hard timeline in your mind, that the pharmacies, which are today not generating cash flow, you would take a hard stance and a…	—	—
Demand	Then we also have launches of the new products in the pipeline.	I think what is happening on the market is that overall, the market has remained healthy in terms of demand.	Okay, so is it right to say that doctors are comfortable using the xenon gas and hence DTPA demand might not normalize at all?
Guidance	On your first question about the pharmacy, we have been indicating that we expect breakeven in FY24 and if you look at the numbers and the trend, we a…	In the coming quarter now, hopefully with Salisbury also coming on stream in the fourth quarter, So the fourth quarter should be lower than this or by…	I don't think there had been any wrong judgment on the timing part, even in my call, I mentioned that we expect to complete this in the mid of CY 2022…
Margin	Regarding radiopharmaceuticals, good to see the radio pharmacy number and EBITDA over there.	Yes as I mentioned that fixed costs remain there, but when you lose the revenue like this entire contribution goes and impacts EBITDA, and some of the…	Just a quick question on some color on the margin profile for the business, I mean, if you look at our margins, you are kind of down from our 23-24% l…
People	—	No, the new facility is fully operating, what we commissioned in September 2021, and we run at a high level of capacity utilization.	—
Pricing	So that had an impact and then there was the impact of the import alert and impact of the Sartan prices and impact of overall the pricing pressure in …	—	—
Revenue growth	And next question is that why the numbers would decline sequentially in terms of topline for radiopharma business and is the margin decline only becau…	Because top line seems to be consistent with the last couple of quarters.	We are very confident that by FY24 the business will be at break even and I also mentioned in my speech that we have seen in the last quarter higher v…